Compare
Vivani Medical, Inc. vs Axogen, Inc. vs Biolife Solutions Inc vs Vaso Corp
| Latest fiscal year | Vivani Medical, Inc. VANI | Axogen, Inc. AXGN | Biolife Solutions Inc BLFS | Vaso Corp VASO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $0 | $225.21M | $96.21M | $89.10M |
| Revenue growth (YoY) | n/a | +20.2% | +28.9% | +2.7% |
| Gross margin | n/a | 74.3% | 64.6% | 61.4% |
| Operating margin | n/a | -3.5% | -17.3% | -3.2% |
| Net margin | n/a | -7.0% | -4.8% | 1.8% |
| Net income | -$26.61M | -$15.70M | -$4.59M | $1.57M |
| EPS (Diluted) | -$0.43 | -$0.34 | -$0.10 | $0.01 |
| Operating cash flow | -$24.32M | $812.0K | $20.11M | $9.27M |
| Free cash flow | -$25.49M | -$2.93M | $10.64M | n/a |
| Cash & equivalents | $16.23M | $35.55M | $33.04M | $35.05M |
| Total assets | $39.39M | $221.69M | $405.88M | $88.35M |
| Total liabilities | $23.66M | $92.84M | $34.00M | n/a |
| Shareholders' equity | $15.73M | $128.85M | $371.89M | $29.43M |
| Return on year-end equity | -169.2% | -12.2% | -1.2% | 5.3% |
| Shares outstanding | 76.43M | 47.20M | 48.20M | 175.95M |
Revenue, most recent five fiscal years
| Fiscal year | Vivani Medical, Inc. | Axogen, Inc. | Biolife Solutions Inc | Vaso Corp |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $225.21M Ended 2025-12-31 | $96.21M Ended 2025-12-31 | $89.10M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $187.34M Ended 2024-12-31 | $74.65M Ended 2024-12-31 | $86.77M Ended 2024-12-31 |
| 2 years earlier | n/a | $159.01M Ended 2023-12-31 | $68.02M Ended 2023-12-31 | $81.02M Ended 2023-12-31 |
| 3 years earlier | n/a | $138.58M Ended 2022-12-31 | $76.24M Ended 2022-12-31 | $79.29M Ended 2022-12-31 |
| 4 years earlier | n/a | $127.36M Ended 2021-12-31 | $119.16M Ended 2021-12-31 | $75.58M Ended 2021-12-31 |